This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
by Zacks Equity Research
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change
biotechnology medical pharmaceuticals
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
by Zacks Equity Research
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change
medical pharmaceuticals
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVONegative Net Change LLYNegative Net Change CRBPNegative Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
REGNNegative Net Change BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
by Zacks Equity Research
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
BMYNegative Net Change BAYRYPositive Net Change EXELNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
by Zacks Equity Research
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.
GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change
aerospace medical pharmaceuticals
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
by Kinjel Shah
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
SNYNegative Net Change RHHBYPositive Net Change PFEPositive Net Change NVONegative Net Change MRKNegative Net Change
pharmaceuticals
FDA Approves GSK's Nucala for Expanded Use in COPD
by Zacks Equity Research
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
REGNNegative Net Change SNYNegative Net Change GSKNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).
GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change WMPositive Net Change TEAMNegative Net Change WPMPositive Net Change
aerospace medical pharmaceuticals
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
by Ekta Bagri
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
BMRNNegative Net Change MRNANegative Net Change NVAXNegative Net Change PRMEPositive Net Change INZYNo Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
by Zacks Equity Research
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
by Zacks Equity Research
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
SNYNegative Net Change BIIBNegative Net Change LLYNegative Net Change VIGLPositive Net Change
pharmaceuticals
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
by Kinjel Shah
While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern
JNJPositive Net Change AMGNNegative Net Change TEVAPositive Net Change KVUEPositive Net Change
pharmaceuticals
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
by Zacks Equity Research
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
JNJPositive Net Change MRKNegative Net Change IBRXNegative Net Change CGONNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
by Zacks Equity Research
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change BBIOPositive Net Change
pharmaceuticals
ARMP Soars 72% in a Month Following Infectious Disease Study Success
by Zacks Equity Research
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change ARMPPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney
by Zacks Equity Research
Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.
KOPositive Net Change PFEPositive Net Change DISNegative Net Change
consumer-discretionary consumer-staples pharmaceuticals
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AZNPositive Net Change NVONegative Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
3 Top Genomics Stocks to Add to Your Portfolio in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
ILMNNegative Net Change BEAMNegative Net Change QURENegative Net Change NTLANegative Net Change CRSPNegative Net Change VERVNegative Net Change
gene-editing gene-therapy genomics medical pharmaceuticals thematic
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
by Sundeep Ganoria
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
by Ekta Bagri
At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent positive estimate revisions
GSKNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
by Zacks Equity Research
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
REGNNegative Net Change BAYRYPositive Net Change HALOPositive Net Change ALLONegative Net Change
biotechnology biotechs dna-sequencing genomics medical pharmaceuticals
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
by Nalak Das
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
KOPositive Net Change PFEPositive Net Change DISNegative Net Change
consumer-discretionary consumer-staples pharmaceuticals
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
by Zacks Equity Research
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
AZNPositive Net Change GSKNegative Net Change BIIBNegative Net Change IONSNegative Net Change
medical pharmaceuticals